The Clot-Promoting Effect of Adenosine-5’-Diphosphate (ADP). II. Site of Action^[*]

Summary

1. ADP accelerates the rate of the “contact” phase of thromboplastin generation by a mechanism which is independent of its known effects on platelets.

2. The acceleratory effect is the result of an interaction between ADP and a plasma factor which is not clearly identifiable with any generally recognized coagulation factor (i. e., factors I-XIII).

^* This investigation was supported by a research grant (AM-04489) and a graduate training grant (AM-5098) from the National Institutes of Arthritis and Metabolic Diseases, National Institutes of Health, Bethesda, Maryland.

^** Present address : Departamento de Hematologia, Hospital General, Centro Médico Nacional. Av. Cuauhtemoc N° 330, México 7, D. F. (Mexico).

^*** Present address : Section of Clinical Pathology, Mayo Clinic, Rochester, Minnesota.

• References

• 1 Hellem A. J. The adhesiveness of human blood platelets in vitro. Thesis. Scand. J. clin. Lab. Invest. 12 51 1960
• 2 Silver M. D, Stehbens W. E. Platelet reaction to adenosine diphosphate in vivo. Nature (Lond.) 205: 91 1965;
• 3 Gaarder A, Jonsen J, Laland S, Hellem A. J, Owren P. A. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature (Lond.) 192: 531 1961;
• 4 Owren P. A. Physiopathologie du temps de saignement. Nouv. Rev. franç. Hémat 3: 280 1963;
• 5 Owren P. A. Nutrition and thrombosing atherosclerosis. Nutr. et Dieta (Basel) 6: 156 1964;
• 6 Odegaard A. E, Skalhegg B. A, Hellem A. J. Increased activity of “Anti-Willebrand Factor” in diabetic plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 11: 27 1964;
• 7 Clayton S, Cross M. J. The aggregation of blood platelets by catecholamines and by thrombin. J. Physiol. (Lond.) 169: 82 1963;
• 8 Caen J, Michel H. L’Activité agregante du sérum. (Plasma déñbriné par la thrombine). Rev. franç. Étud. clin. biol 9: 1001 1964;
• 9 Caen J, Michel H. Agrégation des plaquettes à L’ADP. (Acide adenosine diphosphorique). Rev. franç. Étud. clin. biol 9: 999 1964;
• 10 Nordoy A, Chandler A. B. The influence of dietary fats on the adenosine diphosphate induced platelet thrombosis in the rat. Scand. J. Haemat 1: 202 1964;
• 11 Hellem A. J, Owren P. A. The mechanism of the hemostatic function of blood platelets. Acta haemat. (Basel) 31: 230 1964;
• 12 Born G. V. R, Gross M. J. The aggregation of blood platelets. J. Physiol. (Lond.) 168: 178 1963;
• 13 Mustard J. F, Hegardt B, Rowsell H. G, MacMillan R. L. Effect of adenosine nucleotides on platelet aggregation and clotting time. J. Lab. clin. Med 64: 548 1964;
• 14 Pizzuto J, Giorgio A. J, Didisheim P. The clot-promoting effect of adenosine-5’-diphosphate (ADP). I. Mechanism of action. Thrombos. Diathes. haemorrh. (Stuttg.) 15: 428 1966;
• 15 O’Brien J. R. Some effects on blood coagulation of erythrocytes and other cells. J. clin. Path 22: 45 1959;
• 16 Margolis J. Glass surface and blood coagulation. Nature (Lond.) 178: 805 1956;
• 17 Ratnoff O. D, Grunt J. D. Activation of Hageman factor by solutions of ellagic acid. J. Lab. clin. Med 03: 359 1964;
• 18 Breckenridge R. T, Ratnoff O. D. The role of proaccelerin in human blood coagulation. Evidence that proaccelerin is converted to a prothrombin-converting principle by activated Stuart factor : with notes on the anticoagulant action of soybean trypsin inhibitor, protamine sulfate, and hexadimethrine bromide. J. clin. Invest 44: 302 1965;
• 19 Biggs R, MacFarlane R. G. Human Blood Coagulation. 3rd ed.. F. A. Davis Company; Philadelphia: 1962
• 20 Nossei H. L. The Contact Phase of Blood Coagulation. F. A. Davis Company; Philadelphia: Blackwell Scientific Publications 1964
• 21 Didisheim P, Mibashan R. S. Activation of Hageman factor (factor XII) by long-chain saturated fatty acids. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 346 1963;
• 22 Haanen G, Schoenmakers J. G. G. One-stage assay for Hageman factor (factor XII). Further studies on the role of Hageman factor in blood coagulation. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 557 1963;
• 23 Waaler B. A. Contact activation in the intrinsic blood clotting system. Scand. J. clin. Lab. Invest. 11 37 1959
• 24 Schiffman S. S, Rapaport S. I, Ware A. S, Mihl J. W. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc. Soc. exp. Biol. (N. Y.) 105: 453 1960;
• 25 Pascuzzi C. A, Spittel Jr. J. A, Thompson Jr. J. H, Owen Jr. G. A. Thromboplastin generation accelerator, a newly recognized component of the blood coagulation mechanism present in excess in certain thrombotic states. J. clin. Invest 40: 1006 1961;
• 26 Hathaway W. E, Belhasen L. D, Hathaway H. S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physico-chemical properties. Blood 26: 621 1965;
• 27 Nilsson I. M, Blombäck M, Jorpes E, Blombäck B, Johansson S. von Willebrand disease and its correction with human plasma fraction I—0. Acta med. scand 159: 179 1957;
• 28 Didisheim P, Hattori K, Lewis J. H. Hematologic and coagulation studies in various animal species. J. Lab. clin. Med 53: 866 1959;
• 29 Marcus A. J, Zucker M. D. The Physiology of Blood Platelets. Grune & Stratton; New York and London: 1965
• 30 Soulier J. P. A new adsorption agent for coagulant factors. J. clin. Path 12: 303 1959;